Pharma Journalist -

AbbVie has secured a significant regulatory milestone in Europe after the European Commission approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults, providing…
Read More...

Contraline, a clinical-stage biopharmaceutical company focused on developing innovative male contraceptives, has secured $92.5 million in Series B financing to advance the late-stage…
Read More...

CytomX Therapeutics has expanded its collaboration and licensing agreement with Regeneron Pharmaceuticals to advance the development of next-generation bispecific cancer therapies,…
Read More...

Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an…
Read More...

SystImmune and Bristol Myers Squibb have reported positive Phase 3 results for izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC),…
Read More...

Vertex Pharmaceuticals has moved a step closer to bringing a new treatment option to patients with immunoglobulin A nephropathy (IgAN) after the U.S. Food and Drug Administration (FDA)…
Read More...

Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK)…
Read More...

Servier has announced a major expansion of its neurology and rare disease portfolio through an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal…
Read More...

Bristol Myers Squibb has moved closer to expanding the use of its heart disease therapy Camzyos® (mavacamten) after the U.S. Food and Drug Administration (FDA) accepted a supplemental…
Read More...

Bristol Myers Squibb has received approval from the European Commission for Opdivo® (nivolumab) in combination with the chemotherapy regimen AVD (doxorubicin, vinblastine and…
Read More...